新しい経口抗菌剤Bacmecillinamの尿路感染症に対する有効性, 有用性の評価

DOI

書誌事項

タイトル別名
  • CLINICAL EFFICACY AND USEFULNESS OF KW-1100 (BACMECILLINAM), A NEW ORAL ANTIMICROBIAL AGENT, IN URINARY TRACT INFECTION

抄録

A new oral antimicrobial agent, bacmecillinam, a prodrug of mecillinam was administered in treatment of 149 urinary tract infections. The drug was given at daily doses of 120-320mg. The clinical efficacy was evaluated by the criteria of Japanese UTI committee.<BR>1. The resutls obtained for 84 cases of acute simple urinary tract infection (81 cases of cystitis and 3 cases of pyelonephritis) were as follows: the clinical efficacy was excellent in 49 cases and moderate in 32 cases with the overall efficacy rate being 96%.<BR>2. The overall clinical efficacy obtained for 44 cases of chronic complicated urinary tract infection (40 cases of cystitis and 4 cases of pyelonephritis) were excellent in 7 cases and moderate in 10 cases. In the cases which were infected by organisms sensitive to mecillinam, the clinical efficacy in 17 cases was excellent in 5 and moderate in 7 cases, being a high efficacy rate as 71%.<BR>3. With respect to safety, side effects were observed in 3 cases (2% of total) which were stomach discomfort in two cases and a hard feces in 1 case. These were, however, mild and had no problems for continuing the therapy. In clinical laboratory findings, there were no significant changes in peripheral hematology, liver and kidney function values except a slight elevation of Al-P and BUN in each one case.<BR>4. In conclusion, bacmecillinam showed a markedly high efficacy and a well tolerance in treatment of UTI infected by the strains such asE. coli, Klebsiella, p. mirabilis, Citrobacter which were highly sensitive to the drug.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ